{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:30:25Z","timestamp":1793413825794,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["1R35GM159930"],"award-info":[{"award-number":["1R35GM159930"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012331","name":"LEO Fondet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["1K08AR080266"],"award-info":[{"award-number":["1K08AR080266"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jid.2026.06.1293","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T19:19:47Z","timestamp":1787426387000},"page":"2999-3010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chimeric antigen receptor T-cell therapy in dermatologic autoimmunity: Mechanisms, applications, and future directions"],"prefix":"10.1016","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8838-1443","authenticated-orcid":false,"given":"Catherine Z.","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2725-3809","authenticated-orcid":false,"given":"David","family":"Shon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7910-026X","authenticated-orcid":false,"given":"Yvonne","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7656-0491","authenticated-orcid":false,"given":"Christoph T.","family":"Ellebrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2026.06.1293_bib1","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jid.2026.06.1293_bib67","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jid.2026.06.1293_bib2","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jid.2026.06.1293_bib68","doi-asserted-by":"crossref","first-page":"311","DOI":"10.36849\/JDD.9613","article-title":"Remibrutinib: insights into its mechanism of action and use for dermatologic conditions","volume":"25","author":"Burshtein","year":"2026","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jid.2026.06.1293_bib3","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2026.06.1293_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.70112","article-title":"Associations between pre-existing autoimmunity and chimeric antigen receptor T cell therapy toxicity for cancer treatment","volume":"7","author":"Challener","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.jid.2026.06.1293_bib73","doi-asserted-by":"crossref","first-page":"B18","DOI":"10.1016\/j.jid.2022.05.971","article-title":"LB952 A phase 1 trial of DSG3-CAART cells in mucosal-dominant pemphigus vulgaris patients: preliminary data","volume":"142","author":"Chang","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2026.06.1293_bib66","doi-asserted-by":"crossref","first-page":"912876","DOI":"10.3389\/fimmu.2022.912876","article-title":"Insights into the pathogenesis of bullous pemphigoid: the role of complement-independent mechanisms","volume":"13","author":"Cole","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2026.06.1293_bib6","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/S0140-6736(23)00457-9","article-title":"Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK","volume":"401","author":"Conrad","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2026.06.1293_bib8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/cei\/uxac090","article-title":"Cytokine production by human B cells: role in health and autoimmune disease","volume":"210","author":"de Gruijter","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jid.2026.06.1293_bib9","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2026.06.1293_bib10","doi-asserted-by":"crossref","DOI":"10.1186\/ar3453","article-title":"The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses","volume":"13","author":"Dixon","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jid.2026.06.1293_bib11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jid.2026.06.1293_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12910","article-title":"Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed\/refractory multiple myeloma","volume":"92","author":"Feng","year":"2020","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.jid.2026.06.1293_bib14","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1038\/s41591-025-03937-8","article-title":"Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial","volume":"31","author":"Feng","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jid.2026.06.1293_bib15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cell.2020.03.007","article-title":"Challenges, progress, and prospects of developing therapies to treat autoimmune diseases","volume":"181","author":"Fugger","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jid.2026.06.1293_bib16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ard.2025.06.2132","article-title":"Differential molecular signatures in response to CD19-CAR T cell therapy compared with conventional pharmacotherapy in systemic lupus erythematosus","volume":"85","author":"Garantziotis","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2026.06.1293_bib17","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41409-025-02679-y","article-title":"ICANS risk model in CD19 CAR-T therapy: insights from serum and CSF cytokine profiling","volume":"60","author":"Gomez-Llobell","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jid.2026.06.1293_bib64","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1093\/rheumatology\/keaf190","article-title":"A novel approach to refractory idiopathic inflammatory myopathy: CD19 CAR T-cell therapy-case report and literature review","volume":"64","author":"Haase","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.jid.2026.06.1293_bib18","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jid.2026.06.1293_bib72","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.biopha.2006.10.001","article-title":"Regulation of IgE homeostasis, and the identification of potential targets for therapeutic intervention","volume":"61","author":"Hellman","year":"2007","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jid.2026.06.1293_bib61","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.jid.2026.06.1293_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ccell.2023.11.011","article-title":"Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy","volume":"42","author":"Kaczanowska","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jid.2026.06.1293_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2013.07.002","article-title":"Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology","volume":"39","author":"Kalos","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.jid.2026.06.1293_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jid.2026.06.1293_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1303935","article-title":"Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2026.06.1293_bib69","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.169870","article-title":"Tertiary lymphoid structures sustain cutaneous B cell activity in hidradenitis suppurativa","volume":"9","author":"Lowe","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.jid.2026.06.1293_bib25","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jid.2026.06.1293_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2020.101503","article-title":"Clinical manifestations and treatment of antisynthetase syndrome","volume":"34","author":"Marco","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"suppl 9","key":"10.1016\/j.jid.2026.06.1293_bib27","article-title":"Chimeric autoantigen T-cell receptor (CATCR)-T cell therapies to selectively target autoreactive B cells","volume":"74","author":"Mog","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jid.2026.06.1293_bib71","first-page":"521","article-title":"Metabolic properties of human IgA subclasses","volume":"13","author":"Morell","year":"1973","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jid.2026.06.1293_bib70","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakados","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2026.06.1293_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.581433","article-title":"Antigen specificity enhances disease control by Tregs in vitiligo","volume":"11","author":"Mukhatayev","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2026.06.1293_bib29","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2026.06.1293_bib30","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1016\/S2665-9913(24)00340-0","article-title":"The concept of difficult-to-treat disease in rheumatology: where next?","volume":"7","author":"Nagy","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jid.2026.06.1293_bib31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jid.2026.06.1293_bib32","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/ajt.14175","article-title":"Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor","volume":"17","author":"Noyan","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jid.2026.06.1293_bib34","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","article-title":"Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells","volume":"41","author":"Oh","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jid.2026.06.1293_bib62","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","article-title":"Przepiorka D., et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia","volume":"25","author":"O\u2019Leary","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2026.06.1293_bib35","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"Treg cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jid.2026.06.1293_bib36","series-title":"EBMT\/EHA CAR-T Cell Handbook","first-page":"141","article-title":"Management of immune effector cell-associated neurotoxicity (ICANS)","author":"Rees","year":"2022"},{"key":"10.1016\/j.jid.2026.06.1293_bib37","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jid.2026.06.1293_bib39","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1172\/JCI78088","article-title":"Mechanisms of human autoimmunity","volume":"125","author":"Rosenblum","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jid.2026.06.1293_bib40","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jid.2026.06.1293_bib41","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jid.2026.06.1293_bib42","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s00210-025-04425-z","article-title":"CAR T cell therapy efficacy and safety in SLE: a systematic review and pooled analysis of 47 patients across 10 studies","volume":"399","author":"Sayed","year":"2026","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.jid.2026.06.1293_bib43","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2026.06.1293_bib44","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","article-title":"T cell activation","volume":"27","author":"Smith-Garvin","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jid.2026.06.1293_bib45","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMra061111","article-title":"Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome","volume":"355","author":"Stanley","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2026.06.1293_bib46","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.3389\/fimmu.2019.01744","article-title":"Glucocorticoids-all-rounders tackling the versatile players of the immune system","volume":"10","author":"Strehl","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2026.06.1293_bib47","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2026.06.1293_bib48","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1182\/hematology.2024000535","article-title":"Mitigating and managing infection risk in adults treated with CAR T-cell therapy","volume":"2024","author":"Tabbara","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jid.2026.06.1293_bib49","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1093\/rheumatology\/kead330","article-title":"Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies","volume":"63","author":"Taubmann","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jid.2026.06.1293_bib50","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","article-title":"Second primary malignancies after CAR T-cell therapy: a systematic review and meta-analysis of 5,517 lymphoma and myeloma patients","volume":"30","author":"Tix","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2026.06.1293_bib51","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(24)02504-2","article-title":"Salvage treatment of multi-refractory primary immune thrombocytopenia with CD19 CAR T cells","volume":"405","author":"Trautmann-Grill","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2026.06.1293_bib52","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032713-120257","article-title":"TGF-\u03b2 activation and function in immunity","volume":"32","author":"Travis","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jid.2026.06.1293_bib53","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2026.06.1293_bib63","article-title":"LBS1:03 CTA313, CD19\/BMCA dual targeted allo-CAR-T cell, durable remission in systemtic lupus erythematosus following deep B-cell depletion, suggestive of immune-reset","volume":"13:A338","author":"Wang","year":"2026","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.jid.2026.06.1293_bib54","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2026.06.1293_bib65","doi-asserted-by":"crossref","first-page":"1418768","DOI":"10.3389\/fimmu.2024.1418768","article-title":"Incidentally cured psoriasis in a patient with refracotry\/relapsed diffuse large B-cell lymphoma receiving CD19 CAR-T cell therapy: a case report","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2026.06.1293_bib56","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"issue":"suppl 9","key":"10.1016\/j.jid.2026.06.1293_bib55","article-title":"Preliminary safety, efficacy, and cellular kinetics of CTA311, a CD19-targeted universal CAR-T therapy, for active autoimmune diseases","volume":"77","author":"Wang","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"suppl 9","key":"10.1016\/j.jid.2026.06.1293_bib58","article-title":"RESET-Myositis: clinical trial evaluating rese-cel (resecabtagene autoleucel), a fully human, autologous 4-1BB CD19-CAR T cell therapy in idiopathic inflammatory myopathies","volume":"77","author":"Wilfong","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jid.2026.06.1293_bib59","article-title":"CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon","volume":"16","author":"Wu","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2026.06.1293_bib74","doi-asserted-by":"crossref","first-page":"1529745","DOI":"10.3389\/fimmu.2025.1529745","article-title":"Treatment of pro-B acute lymphoblastic leukemia and severe plaque psoriasis with anti-CD19 CAR T cells: a case report","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X2602676X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X2602676X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:52:13Z","timestamp":1793411533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X2602676X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":65,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0022202X2602676X"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2026.06.1293","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric antigen receptor T-cell therapy in dermatologic autoimmunity: Mechanisms, applications, and future directions","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2026.06.1293","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}